Key result
Natriuretic peptides remain the gold standard biomarker for the diagnosis and prognosis of heart failure, while newer biomarkers like ST2 and galectin-3 offer synergistic prognostic value.
Why the study?
Heart failure diagnosis is often difficult in patients presenting with breathlessness, and while natriuretic peptides are the gold standard biomarker, the evidence behind other biomarkers warrants examination.
This review reinforces the central role of natriuretic peptides in heart failure management according to current guidelines, while summarizing the prognostic potential of newer biomarkers.
Reinforces natriuretic peptides as the HF biomarker standard per guidelines; leaves open routine adoption of ST2 or galectin-3 pending prospective validation.
Heart failure is a clinical condition with complex pathophysiology that involves many different processes. Diagnosis is often difficult in patients presenting for the first time with breathlessness. Many biomarkers have been identified that are elevated in heart failure and their role in assessing prognosis has also been investigated. However, at present the natriuretic peptides appear to be the gold standard biomarker against which the other biomarkers are compared. In this review we will examine the evidence behind the other biomarkers for use in heart failure patients and the current guidelines for their use.
No takes yet. Share an insight, caveat, or question.
Nadar et al. (2019) conducted a review in Heart failure. Biomarkers (e.g., natriuretic peptides, troponin, ST2, galectin-3) was evaluated. Natriuretic peptides remain the gold standard biomarker for the diagnosis and prognosis of heart failure, while newer biomarkers like ST2 and galectin-3 offer synergistic prognostic value.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: